In a specialist article, Kerstin Wolff analyzes the current state of EU regulation on new genomic techniques (NGTs). In February 2024, the European Parliament proposed exempti...
Continue reading
Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization ...
Continue reading
In a significant development, the European Patent Office (EPO) has revoked Salix Pharmaceuticals’ European patent for the antibiotic rifaximin. In decision T 0162/22, the ...
Continue reading
For more awards and information, click here.
